The Effects of Dapagliflozin in Normal Clinical Practice in T2D

Sponsor
University of Milan
Study ID
NCT05418946
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with Dapagliflozin in subjects with type 2 diabetes in normal clinical practice. The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with Dapagliflozin.

Key Dates

Start date
Jun 30, 2022
Status verified
Jun 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
1,400 participants (estimated)

Arms

  • Arm: Treatment group
    Patient in treatment with Dapagliflozin 10 mg/day

Primary Outcome Measure

Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment [ Time Frame: From baseline to 4 months ]

Central Contacts

Related Studies